TY - JOUR
T1 - Is adjuvant chemotherapy necessary for 2014 FIGO stage IC adult granulosa cell tumor?
T2 - Multicentric Turkish study
AU - Erdogan, Ozgur
AU - Kilic, Cigdem
AU - Cakir, Caner
AU - Kilic, Fatih
AU - Oktar, Okan
AU - Ersak, Burak
AU - Sahin, Mustafa
AU - Tokalioglu, Alp
AU - Kocak, Ozgur
AU - Ozturk, Cagatayhan
AU - Gorgulu, Goksen
AU - Gokkaya, Mustafa
AU - Selcuk, Ilker
AU - Korkmaz, Vakkas
AU - Comert, Gunsu Kimyon
AU - Toptas, Tayfun
AU - Ureyen, Isin
AU - Ucar, Gokhan
AU - Taskin, Salih
AU - Tasci, Tolga
AU - Uncu, Dogan
AU - Narin, Mehmet Ali
AU - Boran, Nurettin
AU - Ozdal, Bulent
AU - Tekin, Ozlem Moraloglu
AU - Ustun, Yaprak
AU - Sancı, Muzaffer
AU - Ortac, Firat
AU - Turan, Taner
N1 - Publisher Copyright:
© 2023 John Wiley & Sons Australia, Ltd.
PY - 2024/2
Y1 - 2024/2
N2 - Aim: The aim of our study is to examine the clinical, surgical, and pathological factors of stage 1C adult granulosa cell tumor (AGCT) patients and to investigate the effects of adjuvant therapy on recurrence and survival rates in this patient group. Methods: Out of a total of 415 AGCT patients treated by 10 tertiary oncology centers participating in the study, 63 (15.2%) patients with 2014 FIGO stage IC constituted the study group. The FIGO 2014 system was used for staging. Patient group who received adjuvant chemotherapy was compared with patient group who did not receive adjuvant chemotherapy in terms of disease-free survival (DFS), and disease-specific survival. Results: The 5-year DFS of the study cohort was 89%, and the 10-year DFS was 85%. Those who received adjuvant chemotherapy and those who did not were similar in terms of clinical, surgical and pathological factors, except for peritoneal cytology. In the univariate analysis, none of the clinical, surgical or pathological factors were significant for DFS. Adjuvant chemotherapy and type of treatment protocol had no impact on DFS. Conclusion: Adjuvant chemotherapy was not associated with improved DFS and overall survival in stage IC AGCT. Multicentric and randomized controlled studies are needed for early stage AGCT in order to confirm these results and reach accurate conclusions.
AB - Aim: The aim of our study is to examine the clinical, surgical, and pathological factors of stage 1C adult granulosa cell tumor (AGCT) patients and to investigate the effects of adjuvant therapy on recurrence and survival rates in this patient group. Methods: Out of a total of 415 AGCT patients treated by 10 tertiary oncology centers participating in the study, 63 (15.2%) patients with 2014 FIGO stage IC constituted the study group. The FIGO 2014 system was used for staging. Patient group who received adjuvant chemotherapy was compared with patient group who did not receive adjuvant chemotherapy in terms of disease-free survival (DFS), and disease-specific survival. Results: The 5-year DFS of the study cohort was 89%, and the 10-year DFS was 85%. Those who received adjuvant chemotherapy and those who did not were similar in terms of clinical, surgical and pathological factors, except for peritoneal cytology. In the univariate analysis, none of the clinical, surgical or pathological factors were significant for DFS. Adjuvant chemotherapy and type of treatment protocol had no impact on DFS. Conclusion: Adjuvant chemotherapy was not associated with improved DFS and overall survival in stage IC AGCT. Multicentric and randomized controlled studies are needed for early stage AGCT in order to confirm these results and reach accurate conclusions.
KW - adjuvant chemotherapy
KW - granulosa cell tumor
KW - ovarian neoplasm
KW - sex-cord stromal tumor
UR - http://www.scopus.com/inward/record.url?scp=85153621596&partnerID=8YFLogxK
U2 - 10.1111/ajco.13942
DO - 10.1111/ajco.13942
M3 - Article
C2 - 37096294
AN - SCOPUS:85153621596
SN - 1743-7555
VL - 20
SP - 46
EP - 54
JO - Asia-Pacific Journal of Clinical Oncology
JF - Asia-Pacific Journal of Clinical Oncology
IS - 1
ER -